Amidotrizoic acid is a water-soluble, iodinated contrast agent used primarily in radiographic imaging to enhance the visibility of vascular structures, urinary tract, and gastrointestinal organs during X-ray and CT procedures. It works by increasing the radiodensity of the blood or luminal contents, allowing improved contrast between tissues and organs. Developed in the mid-20th century as part of efforts to create safer and more effective contrast media than earlier ionic and poorly soluble agents, amidotrizoic acid became widely used due to its high water solubility, rapid renal excretion, and relatively low toxicity. Over time, it has been formulated in various concentrations and combinations for intravenous, intra-arterial, or gastrointestinal administration, remaining an important diagnostic tool in medical imaging while requiring careful monitoring for hypersensitivity or renal adverse effects.
BRAND NAMES
Gastrografin – commonly used for gastrointestinal imaging and as a contrast agent in X-ray or CT studies
Urografin – primarily used for urinary tract imaging and intravenous urography.
MECHANISM OF ACTION
Amidotrizoic acid is a radiopaque contrast agent that works by absorbing X-rays due to the presence of multiple iodine atoms in its molecular structure. When administered orally, rectally, or intravenously, it distributes into the gastrointestinal tract, blood vessels, or urinary system, depending on the route.
PHARMACOKINETICS
Absorption
Amidotrizoic acid is a water-soluble contrast agent that is poorly absorbed from the gastrointestinal tract when administered orally or rectally, allowing it to remain largely within the lumen for imaging studies of the digestive tract.
Distribution
Amidotrizoic acid has a limited volume of distribution, approximately 0.25–0.35 L/kg when administered intravenously, reflecting its confinement primarily to the plasma and extracellular fluid.
Metabolism
Amidotrizoic acid is not metabolized in the body. After administration, it remains chemically unchanged, whether it is given orally, rectally, or intravenously. Its iodine-containing structure is stable, which allows it to act effectively as a radiopaque contrast agent without undergoing biotransformation.
Elimination
Amidotrizoic acid is primarily eliminated unchanged via the kidneys through glomerular filtration, with most of the drug excreted in the urine within 24 hours after intravenous administration. When administered orally or rectally, it is largely excreted in the feces without significant systemic absorption.
PHARMACODYNAMICS
Amidotrizoic acid functions as a radiopaque contrast agent by virtue of its high iodine content, which allows it to absorb X-rays and create a clear contrast between body structures on radiographic or CT imaging. When administered, it remains primarily in the vascular, extracellular, or gastrointestinal compartments, depending on the route, without interacting with cellular receptors or metabolic pathways.
ADMINISTRATION
Amidotrizoic acid can be administered orally, rectally, or intravenously depending on the imaging study. Oral administration is used to visualize the esophagus, stomach, and intestines, while rectal administration via enemas is employed for imaging the colon and rectum.
DOSAGE AND STRENGTH
Amidotrizoic acid is supplied as aqueous solutions with varying iodine concentrations, typically ranging from 292 mg/mL to 652 mg/mL, depending on the formulation and intended imaging study. For oral administration, doses generally range from 30 to 90 mL of a 76% solution, often diluted according to protocol, to visualize the gastrointestinal tract.
DRUG INTERACTIONS
Amidotrizoic acid can interact with several medications, primarily through effects on renal function and fluid balance. Co-administration with nephrotoxic drugs, such as aminoglycosides, cisplatin, or NSAIDs, may increase the risk of renal impairment. Use with diuretics can alter fluid and electrolyte balance, potentially leading to volume depletion or imbalances.
FOOD INTERACTIONS
Amidotrizoic acid generally has minimal interactions with food, as it is a contrast agent rather than a systemic drug. However, for oral gastrointestinal imaging, patients are usually advised to fast for several hours before administration to ensure the stomach and intestines are empty, which improves the clarity of imaging.
CONTRAINDICATIONS
Amidotrizoic acid is contraindicated in patients with a known hypersensitivity to iodinated contrast agents or any component of the formulation, as exposure may trigger severe allergic or anaphylactic reactions. It should be avoided in individuals with severe dehydration or uncompensated heart failure, since its osmotic effects can worsen fluid imbalance.
SIDE EFFECTS
Nausea and vomiting – most common, especially with oral or rectal administration
Diarrhea or abdominal cramping – due to osmotic effects in the gastrointestinal tract
Headache or dizziness – occasionally reported
Allergic reactions – ranging from mild rash or urticaria to severe anaphylaxis
Flushing or warmth – transient vasomotor effects.
TOXICITY
Amidotrizoic acid toxicity is uncommon but can occur, particularly with high doses, rapid administration, or in patients with pre-existing renal, cardiac, or fluid balance disorders. Toxic effects are primarily related to its osmotic and iodine load, which can cause renal impairment, fluid overload, electrolyte disturbances, and hemodynamic changes.
